EDUCATION

Medical School

  • Brown University School of Medicine , Providence , RI
Graduate School
  • Brown University School of Medicine , Providence , RI

Fellowship

Anatomy and Cellular Biology
  • Tufts University School of Medicine , Boston , MA

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Gordon LB, Shappell H, Massaro J, D'Agostino RB, Brazier J, Campbell SE, Kleinman ME, Kieran MW. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018 04 24; 319(16):1687-1695. View abstract
  2. Prakash A, Gordon LB, Kleinman ME, Gurary EB, Massaro J, D'Agostino R, Kieran MW, Gerhard-Herman M, Smoot L. Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA Cardiol. 2018 Apr 01; 3(4):326-334. View abstract
  3. DuBose AJ, Lichtenstein ST, Petrash NM, Erdos MR, Gordon LB, Collins FS. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc Natl Acad Sci U S A. 2018 Apr 17; 115(16):4206-4211. View abstract
  4. Bassir SH, Chase I, Paster BJ, Gordon LB, Kleinman ME, Kieran MW, Kim DM, Sonis A. Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome. J Periodontol. 2018 Feb 19. View abstract
  5. Gordon LB, Campbell SE, Massaro JM, D'Agostino RB, Kleinman ME, Kieran MW, Moses MA. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatr Res. 2018 Jan 17. View abstract
  6. Greer MM, Kleinman ME, Gordon LB, Massaro J, D'Agostino RB, Baltrusaitis K, Kieran MW, Gordon CM. Pubertal Progression in Female Adolescents with Progeria. J Pediatr Adolesc Gynecol. 2017 Dec 16. View abstract
  7. Mantagos IS, Kleinman ME, Kieran MW, Gordon LB. Ophthalmologic Features of Progeria. Am J Ophthalmol. 2017 Oct; 182:126-132. View abstract
  8. Gabriel D, Shafry DD, Gordon LB, Djabali K. Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts. Oncotarget. 2017 Sep 12; 8(39):64809-64826. View abstract
  9. Gabriel D, Gordon LB, Djabali K. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype. PLoS One. 2016; 11(12):e0168988. View abstract
  10. Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, Gordon LB. A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. J Med Genet. 2017 03; 54(3):212-216. View abstract
  11. Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, Jiménez-Borreguero LJ, Guadix JA, Osorio FG, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, Gordon LB, Jalife J, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V. Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):E7250-E7259. View abstract
  12. Gordon LB, Kleinman ME, Massaro J, D'Agostino RB, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12; 134(2):114-25. View abstract
  13. Gordon LB, Kieran MW, Kleinman ME, Misteli T. The decision-making process and criteria in selecting candidate drugs for progeria clinical trials. EMBO Mol Med. 2016 07; 8(7):685-7. View abstract
  14. Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132:249-64. View abstract
  15. Gabriel D, Roedl D, Gordon LB, Djabali K. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts. Aging Cell. 2015 Feb; 14(1):78-91. View abstract
  16. Miyamoto MI, Djabali K, Gordon LB. Atherosclerosis in ancient humans, accelerated aging syndromes and normal aging: is lamin a protein a common link? Glob Heart. 2014 Jun; 9(2):211-8. View abstract
  17. Gordon LB, Massaro J, D'Agostino RB, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014 Jul 01; 130(1):27-34. View abstract
  18. Gordon LB, Rothman FG, López-Otín C, Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014 Jan 30; 156(3):400-7. View abstract
  19. Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG. Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol. 2014 Mar-Apr; 31(2):196-202. View abstract
  20. Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013 Jul 30; 81(5):427-30. View abstract
  21. Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013 May; 34(5):1091-7. View abstract
  22. Gordon LB, Cao K, Collins FS. Progeria: translational insights from cell biology. J Cell Biol. 2012 Oct 01; 199(1):9-13. View abstract
  23. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16666-71. View abstract
  24. Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol. 2012 Sep; 42(9):1089-98. View abstract
  25. Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biol Open. 2012 Jun 15; 1(6):516-26. View abstract
  26. Ullrich NJ, Silvera VM, Campbell SE, Gordon LB. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1512-8. View abstract
  27. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension. 2012 Jan; 59(1):92-7. View abstract
  28. Guardiani E, Zalewski C, Brewer C, Merideth M, Introne W, Smith AC, Gordon L, Gahl W, Kim HJ. Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome. Laryngoscope. 2011 Oct; 121(10):2250-5. View abstract
  29. Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, Gordon LB. Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1201-7. View abstract
  30. Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW. Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res. 2011 Jul; 26(7):1670-9. View abstract
  31. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, Gordon LB. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010 Nov; 30(11):2301-9. View abstract
  32. Marji J, O'Donoghue SI, McClintock D, Satagopam VP, Schneider R, Ratner D, Worman HJ, Gordon LB, Djabali K. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS One. 2010 Jun 15; 5(6):e11132. View abstract
  33. Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, Introne WJ, Gahl WA, Hart TC. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis. 2009 Apr; 15(3):187-95. View abstract
  34. Gordon LB, Harling-Berg CJ, Rothman FG. Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science. J Gerontol A Biol Sci Med Sci. 2008 Aug; 63(8):777-87. View abstract
  35. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008 Mar; 87(2):70-86. View abstract
  36. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008 Feb 07; 358(6):592-604. View abstract
  37. McClintock D, Ratner D, Lokuge M, Owens DM, Gordon LB, Collins FS, Djabali K. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One. 2007 Dec 05; 2(12):e1269. View abstract
  38. Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics. 2007 Oct; 120(4):834-41. View abstract
  39. Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics. 2007 Oct; 120(4):824-33. View abstract
  40. Lemire JM, Patis C, Gordon LB, Sandy JD, Toole BP, Weiss AS. Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts. Mech Ageing Dev. 2006 Aug; 127(8):660-9. View abstract
  41. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, Wight TN, Nabel EG, Collins FS. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3250-5. View abstract
  42. McClintock D, Gordon LB, Djabali K. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2154-9. View abstract
  43. Scaffidi P, Gordon L, Misteli T. The cell nucleus and aging: tantalizing clues and hopeful promises. PLoS Biol. 2005 Nov; 3(11):e395. View abstract
  44. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2005 Sep 06; 102(36):12879-84. View abstract
  45. Gordon LB, Harten IA, Patti ME, Lichtenstein AH. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. J Pediatr. 2005 Mar; 146(3):336-41. View abstract
  46. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):8963-8. View abstract
  47. Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, Hascall V, Toole BP. Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome. Hum Genet. 2003 Jul; 113(2):178-87. View abstract
  48. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003 May 15; 423(6937):293-8. View abstract
  49. Gordon LB, Nolan SC, Ksander BR, Knopf PM, Harling-Berg CJ. Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. J Neuroimmunol. 1998 Aug 01; 88(1-2):77-84. View abstract
  50. Gordon LB, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol. 1997 Sep 01; 159(5):2399-408. View abstract
  51. Gordon LB, Knopf PM, Cserr HF. Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol. 1992 Sep; 40(1):81-7. View abstract